/

Workspace

Research & Review

Writing & Publishing

Data & Analysis

Utilities

Account

User Settings

J

Jagadeswara Rao Earla

Merck & Co., Inc., Rahway, NJ, USA (United States)(US)

Claim or correct this author profile

Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.

75

Papers

174

Citations

8

h-index

6

i10-index

Jagadeswara Rao Earla is an academic researcher from Merck & Co., Inc., Rahway, NJ, USA (United States). The author has contributed to research in topics: Breast Cancer Treatment Studies & Advanced Breast Cancer Therapies & Multiple Sclerosis Research Studies. The author has an h-index of 8, co-authored 64 publications.

ORCID: 0000-0002-6688-5273

Research Topics

Breast Cancer Treatment Studies Advanced Breast Cancer Therapies Multiple Sclerosis Research Studies BRCA gene mutations in cancer Health Systems, Economic Evaluations, Quality of Life

Papers by this author

works

Antimuscarinic Discontinuation in Patients with Overactive Bladder in Nursing Homes: A Retrospective Study of Medicare Beneficiaries

2020 · Advances in Therapy · 4 citations

https://doi.org/10.1007/s12325-020-01412-z

Rajender R. Aparasu Sneha Sura Jagadeswara Rao Earla Aki Shiozawa

Real-World Germline BRCA Testing, Poly(ADP-ribose) Polymerase Inhibitor Utilization, and Survival Outcomes in Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer

2025 · JCO Precision Oncology · 3 citations

https://doi.org/10.1200/po-24-00814

Siddhartha Yadav Fergus J. Couch Sam Hillman Linlin Luo

Real-world perioperative treatment patterns and economic burden of recurrence in early-stage HER2-negative breast cancer: a SEER-Medicare study

2024 · Journal of Medical Economics · 1 citations

https://doi.org/10.1080/13696998.2024.2439228

Jagadeswara Rao Earla Kalé Kponee-Shovein Allison W. Kurian Malena Mahendran

MT22 Mapping Definitions of Patient-Facing Digital Health Intervention in Published Frameworks Against the PICOTS-ComTeC Minimum Information Framework

2024 · Value in Health · 0 citations

https://doi.org/10.1016/j.jval.2024.03.1560

Z Zrubka A Champion AP Holtorf Di Bidino R

Correlation Between Disease-Free Survival Endpoints and Overall Survival in Elderly Patients with Early-Stage HER2-Negative Breast Cancer: A SEER-Medicare Analysis

2024 · Advances in Therapy · 0 citations

https://doi.org/10.1007/s12325-024-03074-7

Jagadeswara Rao Earla Allison W. Kurian Kalé Kponee-Shovein Malena Mahendran

CO161 Developing and Evaluating Definitions of Real-World (rw) Clinical Endpoints for Patients with Early-Stage Triple Negative Breast Cancer (esTNBC) Using a US Secondary Database

2025 · Value in Health · 0 citations

https://doi.org/10.1016/j.jval.2025.04.246

Xiaohan Hu Amin Haiderali Jagadeswara Rao Earla Giovanna Cruz

Research topics

topics

Breast Cancer Treatment Studies

Advanced Breast Cancer Therapies

Multiple Sclerosis Research Studies

BRCA gene mutations in cancer

Health Systems, Economic Evaluations, Quality of Life

Chat about Author

Papers

Chat

Click to start Chat